Inogen Announces the Launch of Aurora CPAP Masks for Obstructive Sleep Apnea in the United States

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Positive)

Key Terms

cpap medical

A CPAP (continuous positive airway pressure) device is a machine that gently blows a steady stream of air through a mask to keep a person’s breathing passages open during sleep, commonly used to treat sleep apnea. For investors, CPAPs matter because they represent a medical-device market with recurring sales of equipment and disposable supplies, subject to safety reviews, insurance reimbursement rules and regulatory approvals that can affect a maker’s revenue and reputation.

obstructive sleep apnea medical

Obstructive sleep apnea is a common medical condition where the throat repeatedly narrows or closes during sleep, causing short pauses in breathing, drops in blood oxygen and fragmented rest. It matters to investors because it creates ongoing demand for medical devices, diagnostics, treatments and sleep-monitoring services, and it can affect population health, workforce productivity and healthcare spending—like a recurring leak in a system that requires continual repair and monitoring.

nasal pillows medical

Nasal pillows are small, soft cushions that fit just inside the nostrils and create a seal to deliver pressurized air for sleep‑disorder breathing devices like CPAP machines. Think of them like earbuds that channel air rather than sound: their comfort, fit and durability strongly influence whether users stick with therapy, which affects device sales, recurring consumable replacement revenue and competitive appeal in the sleep‑care market.

510(k) regulatory

A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.

01/07/2026 - 08:30 AM

Expansion Aligns with Innovation and Growth Strategy

GOLETA, Calif.--(BUSINESS WIRE)-- Inogen, Inc. (Nasdaq: INGN), a leading medical technology company specializing in innovative respiratory products for homecare use, today announced the launch of Aurora CPAP masks, a new product within the expanding Inogen portfolio. Aurora’s introduction marks a significant milestone in Inogen’s strategy to expand its respiratory care portfolio and now bring quality, high-performing masks to patients indicated for obstructive sleep apnea (OSA).

Strategic Positioning and Market Opportunity

Engineered for superior comfort, reliability, and usability, Aurora Masks establishes Inogen’s presence in the growing sleep-therapy market and expands Inogen’s addressable market opportunity. The company intends to leverage its existing distribution channels and partnerships to bring Aurora CPAP masks to customers and strengthen relationships with providers.

“The launch of Aurora CPAP masks represents a pivotal step in Inogen’s evolution towards expanding into a broad home care respiratory solutions company and our entry into the sleep apnea market,” said Kevin Smith, President and Chief Executive Officer. “With Aurora Masks, we are bringing the same patient-centric innovation that defines our respiratory solutions to a new category, delivering comfort, performance, and reliability. We see Aurora Masks as a growth catalyst that reinforces our commitment to leading in patient outcomes in home respiratory care.”

Aurora Masks launch is supported by a patient-use study, in which the majority of patients reported being highly satisfied with the Aurora masks¹.

The Aurora Mask portfolio—which includes the F1 Full Face, N1 Nasal Cushion, and P1 Nasal Pillows—is specifically designed to meet the diverse needs of most patients using CPAP devices. Aurora Masks provide options for different facial structures and therapy needs, promoting patient-focused care and encouraging consistent use in sleep and respiratory therapy.

Key Features

High-Quality Headgear: features a triple-material design with ultrasonic edge sealing technology, promoting comfort and durability.
Comfortable Cushion Design: Medical-grade rebound silicone cushion is soft, airtight, and hypoallergenic – designed to reduce facial pressure and improve patient fit and comfort.
Quiet Honeycomb Vent Design: Promotes a peaceful sleep environment for users and partners.
Simple Maintenance: Easy to assemble, disassemble, and clean for everyday convenience.
Universal Compatibility: Works seamlessly with most CPAP devices.
FDA 510(k) Cleared: Meets rigorous safety and performance standards.

Aurora CPAP masks are now offered through certified partners. For further details, please visit Inogen.com/Products.

¹AMG CPAP Mask Trial Study, August 2025: 30-day study involving 140 patients undergoing CPAP therapy for at least six months, with usage of at least five nights per week and a minimum of four hours per night.

About Inogen

Inogen, Inc. (Nasdaq: INGN) is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class respiratory therapy devices used to deliver care to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products widely available, allowing patients the chance to manage the impact of their disease.

For more information, please visit www.inogen.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that are not historical facts, including, but not limited to, statements regarding Inogen’s future business plans, market opportunities, financial outlook, growth strategies, and anticipated operational results, are forward-looking statements. Words such as “aims,” “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks and uncertainties relating to the potential benefits of Inogen’s collaboration with Yuwell; market acceptance of its products; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Inogen’s business operating results are contained in its Annual Report on Form 10-K for the period ended December 31, 2024, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.